IFRX
|InflaRx N.V.
NASDAQ
USD 0.88
+0.07|+8.64%
Current Price
USD 0.88
Change
+USD 0.07 (8.64%)
P/E Ratio
Dividend Yield
Market Cap
123.30M
Volume
724,496
Open
USD 0.79
Previous Close
USD 0.81
52-Week High
USD 2.81
52-Week Low
USD 0.71
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa,...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Niels C. Riedemann M.D., Ph.D.
Employees:74
Headquarters:Jena, Germany
Website:www.inflarx.de
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions